Literature DB >> 21960916

Natalizumab for Moderate-to-Severe Crohn's Disease.

Gerald W Dryden1.   

Abstract

Entities:  

Year:  2008        PMID: 21960916      PMCID: PMC3093736     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  3 in total

1.  Natalizumab induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Jean Frédéric Colombel; Roberts Enns; Brian G Feagan; Stephen B Hanauer; Ian C Lawrance; Remo Panaccione; Martin Sanders; Stefan Schreiber; Stephan Targan; Sander van Deventer; Ronald Goldblum; Darrin Despain; Gary S Hogge; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-11-03       Impact factor: 91.245

2.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Authors:  Stephan R Targan; Brian G Feagan; Richard N Fedorak; Bret A Lashner; Remo Panaccione; Daniel H Present; Martina E Spehlmann; Paul J Rutgeerts; Zsolt Tulassay; Miroslava Volfova; Douglas C Wolf; Chito Hernandez; Jeffrey Bornstein; William J Sandborn
Journal:  Gastroenterology       Date:  2007-03-21       Impact factor: 22.682

3.  Natalizumab for active Crohn's disease.

Authors:  Subrata Ghosh; Eran Goldin; Fiona H Gordon; Helmut A Malchow; Jørgen Rask-Madsen; Paul Rutgeerts; Petr Vyhnálek; Zdena Zádorová; Tanya Palmer; Stephen Donoghue
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.